We are honored to be part of Closing in on Cancer, hosted by Portal Innovations and Cancer Moonshot, in Houston on November 19th. CEO Dede Willis will be on the panel 'Next Gen Catalysts of Change,'?discussing how emerging cancer startups are driving new therapies and diagnostics to achieve Cancer Moonshot’s mission of cutting cancer mortality in half by 2047. Portal Innovations, LLC E.J. Reedy CancerX Moonshot Be part of the future of cancer treatment – register here: https://lnkd.in/gngmMCAk
关于我们
Orbit Genomics is transforming complex disease diagnosis, treatment and prevention through early warning genomics. Our patent pending OrbiSeq? platform analyzes novel genomic markers which uniquely reflect not only inherited predisposition to disease, but also risk acquired from lifestyle and environmental exposures. OrbiSeq can be applied to diagnose, treat and help prevent complex diseases including cancer, heart disease and neurological diseases. Our first product is an aid to diagnosis for lung cancer, the world’s deadliest cancer and the only major one without a routine screening test. Diagnosis often requires an expensive and invasive biopsy. Our simple blood test will eliminate unnecessary biopsies.
- 网站
-
https://www.orbitgenomics.com
Orbit Genomics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- Boulder，CO
- 类型
- 私人持股
地点
-
主要
获取路线
US，CO，Boulder，80301
Orbit Genomics员工
动态
-
We are delighted to share that Orbit Genomics was awarded a $2 million Direct to Phase II SBIR Grant from NIH/NCI to develop a subtyping lung cancer test. This test will be the second generation of OrbiSeq-L, a simple blood test that diagnoses lung cancer in patients that have indeterminate pulmonary nodules. The added subtyping capability will substantially expand the use of our test while improving patient outcomes, further reducing the need for biopsies, and significantly reducing costs. The grant review process featured an exceptionally rigorous peer reviewed evaluation of our technology platform by experts internal and external to NIH/NCI, providing robust validation of our scientific and business approach and its potential to drive innovation in the field.
-
Looking forward to working with Imidex to enhance lung cancer detection. We at Orbit Genomics are very proud of the breadth of our OrbiSeqTM technology platform and we are excited to begin working on this game-changing collaboration. https://lnkd.in/g6hi9wZk
IMIDEX and Orbit Genomics have partnered to address the challenge of early lung cancer detection. Imidex’s AI-driven chest x-ray technology identifies lung nodules with 83% sensitivity, offering a broader screening reach compared to traditional methods. Orbit Genomics then provides deeper genomic insights through its OrbiSeq-L platform, helping to clarify indeterminate findings. This collaboration is designed to bridge the gap in lung cancer diagnosis by combining advanced imaging with targeted genomics. Read more about how this partnership could impact early diagnosis and patient outcomes: https://lnkd.in/e3N7UfM5 #Bioengineering #LungCancer #AI #Healthcare #PrecisionMedicine Wes Bolsen Dede Willis
-
Thankful for the opportunity to be part of this fantastic program. Congratulations to all of the amazing companies and heartfelt thanks to the sponsors, our champions and mentors. Together, we can end cancer as we know it!
?? It’s graduation day for CancerX’s Accelerator program's inaugural cohort of startups! For four months, The Blue Box Biomedical Solutions, C the Signs, Cancer Insights, Curiva, EnteroTrack LLC., Gesund.ai, Gray Oncology Solutions, Lind, Mika, Navya Care, Oatmeal Health, Orbit Genomics, Realyze Intelligence, Reimagine Care, SurvivorPlan, XanthosHealth, collaborated with Accelerator Champions, Mentors, federal partners, and CancerX members across the healthcare ecosystem to generate and scale ideas that have the potential to save lives and improve the experience of cancer patients and their caregivers—both strongly tied to CancerX and the Cancer Moonshot goals. The startups shared ideas for digital innovation in clinical research, screening and diagnosis, treatment and management, clinical operations, and patient, caregiver, and survivor experience, and were selected from a strong pool of over 100 startup applicants. Judging for the CancerX Accelerator was led by Moffitt Cancer Center and MassChallenge alongside CancerX Accelerator Champions Atrium Health, AstraZeneca, Amazon Web Services (AWS), Debiopharm, Dell Technologies, Intel Corporation, Oncology Ventures, Reveal HealthTech, and UC Davis Health with insight and observation by our federal partners. By graduating from the Accelerator program, these startups now have a roadmap to successfully scale their company, an opportunity to move forward with their sponsor, and a strong community supporting their development. And with 16 empowered startups poised for success and equipped with the tools and expertise needed to bring their ideas to life, significant strides are being made in revolutionizing the fight against cancer through digital innovation. ?? Please join us in recognizing and celebrating these Startups, their Champions, and Mentors, and the incredible impact of their progress in CancerX’s mission to unleash the power of innovation to reduce the burden of cancer for everyone. We’re thrilled to offer you the chance to be involved in our next cohort! Submissions for Cohort 2025 will open soon, and if you want to join the CancerX Accelerator as a Startup, Champion, or Mentor, be the first to hear about the details for Cohort 2025 by signing up here: https://lnkd.in/ebpXGwXa
-